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Abstract
Introduction Outcome after cardiac arrest is mostly determined
by the degree of hypoxic brain damage. Patients recovering from
cardiopulmonary resuscitation are at great risk of subsequent
death or severe neurological damage, including persistent
vegetative state. The early definition of prognosis for these
patients has ethical and economic implications. The main
purpose of this study was to investigate the prognostic value of
serum neuron-specific enolase (NSE) in predicting outcomes in
patients early after in-hospital cardiac arrest.
Methods Forty-five patients resuscitated from in-hospital
cardiac arrest were prospectively studied from June 2003 to
January 2005. Blood samples were collected, at any time
between 12 and 36 hours after the arrest, for NSE
measurement. Outcome was evaluated 6 months later with the
Glasgow outcome scale (GOS). Patients were divided into two
groups: group 1 (unfavorable outcome) included GOS 1 and 2
patients; group 2 (favorable outcome) included GOS 3, 4 and 5
patients. The Mann–Whitney U test, Student's t test and
Fisher's exact test were used to compare the groups.
Results The Glasgow coma scale scores were 6.1 ± 3 in group
1 and 12.1 ± 3 in group 2 (means ± SD; p < 0.001). The mean
time to NSE sampling was 20.2 ± 8.3 hours in group 1 and 28.4
± 8.7 hours in group 2 (p = 0.013). Two patients were excluded
from the analysis because of sample hemolysis. At 6 months,
favorable outcome was observed in nine patients (19.6%). Thirty
patients (69.8%) died and four (9.3%) remained in a persistent
vegetative state. The 34 patients (81.4%) in group 1 had
significantly higher NSE levels (median 44.24 ng/ml, range 8.1
to 370) than those in group 2 (25.26 ng/ml, range 9.28 to
55.41; p = 0.034).
Conclusion Early determination of serum NSE levels is a
valuable ancillary method for assessing outcome after in-
hospital cardiac arrest.
Introduction
Since the introduction of closed-chest cardiac massage in
1960 [1] there have been several advances in cardiopulmo-
nary resuscitation [2]. In spite of that, morbidity and mortality
associated with cardiac arrest remain extremely high [3,4],
with prognosis ranging from mild to moderate disability to per-
sistent vegetative state. It is estimated that 80% of sudden
death survivors remain in a coma for various lengths of time,
and a full neurological recovery is still rare [5]. The possibility
of irreversible anoxic brain damage must be taken into account
soon after the arrest.
In this scenario, an accurate prognostic evaluation of cardiac
arrest patients may have major ethical and economic conse-
quences. Currently, prognosis is based on several clinical,
neuroimaging and electrophysiological methods [6-9]. How-
ever, applying these methods is often difficult as a result of
sedation and the hemodynamic instability commonly seen inPage 1 of 6
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low-cost alternative that may be more suitable for this purpose.
Neuron-specific enolase (NSE) is a known marker of ischemic
brain damage and has already been evaluated in traumatic
brain injury [10], stroke [11] and anoxic encephalopathy after
cardiac arrest [12,13]. NSE, the neuronal form of the glycolytic
enzyme enolase, is found almost exclusively in neurons and
cells of neuroendocrine origin. It is a dimeric form com-
pounded of two γ subunits that converts 2-phosphoglycerate
into phosphoenolpyruvate, measurable in blood and cerebros-
pinal fluid [14].
As far as we know, there have been no studies focused on the
prognostic value of NSE in patients surviving in-hospital car-
diac arrest. The objective of this study was to prospectively
evaluate the association of early NSE levels with patient out-
come 6 months after in-hospital cardiac arrest, as measured
by the Glasgow outcome scale (GOS) [15]. Our secondary
goal was to establish a cutoff NSE level that could indicate
unfavorable outcome (death or persistent vegetative state).
Materials and methods
Patients
We prospectively evaluated 45 patients who survived an in-
hospital cardiac arrest in the period from June 2003 to January
2005 at the Hospital de Clínicas de Porto Alegre and the
Complexo Hospitalar Santa Casa, two tertiary-care university
hospitals in Porto Alegre, Brazil. We included patients who
were successfully resuscitated after in-hospital cardiac arrest,
as defined by the absence of palpable pulse and effective
spontaneous ventilation with initial rhythm ventricular fibrilla-
tion, pulseless ventricular tachycardia, pulseless electrical
activity and asystole, who survived for at least 12 hours after
the event and for whom informed consent was obtained from
the next of kin. The study was approved by the ethics commit-
tees of both hospitals. We excluded patients under the age of
16 years, those presenting drug intoxication, accidental or
therapeutic hypothermia, those with neoplastic diseases
known to increase NSE levels, stroke (ischemic and/or hemor-
rhagic) or traumatic brain injury in the previous 30 days, and
patients subjected to extracorporeal circulation in the previous
30 days.
Patients were evaluated in terms of age, sex, duration of resus-
citation efforts, Glasgow coma scale (GCS) score, pupillary
reactivity to light, need of sedation, and time interval to blood
sampling for NSE measurement. Resuscitation protocols fol-
lowed American Heart Association guidelines [16]. Every
resuscitated patient was admitted to an intensive care unit and
the care provided followed the routine of the units, without
interference from the investigators. Neurological examinations
were performed together with blood sampling for NSE meas-
urement between 12 and 36 hours after cardiac arrest.
Attending physicians and the critical care team were unaware
of the results of NSE measurements. None of the patients had
a do-not-resuscitate order and there was no limitation of life
support.
Procedure
Blood samples were withdrawn by peripheral vein puncture
and centrifuged for 10 minutes at 2,500 rotations per minute.
Serum (1 ml) was frozen and stored at -86°C. Hemolyzed sam-
ples were considered lost. NSE measurements were per-
formed with an electrochemiluminescence immunoassay
(ECLIA), using a sandwich technique, in duplicate, with NSE
kits (Roche, Mannheim, Germany) and the Elecsys 2010 ana-
lyzer (Roche Diagnostics, Mannheim, Germany). NSE meas-
urements were also performed in seven control individuals.
The surviving patients were contacted by phone [17,18], 6
months after the date of the cardiac arrest, to evaluate neuro-
logical status measured by the GOS. The performance cate-
gories were defined as follows: GOS 1, death; GOS 2,
persistent vegetative state; GOS 3, severe disability (unable to
live independently, but capable of following commands); GOS
4, moderate disability (able to live independently, but unable to
return to work); GOS 5, mild or no disability (able to return to
work). For the purpose of this study, outcomes were separated
into two groups: group 1 included patients who died or
remained in a persistent vegetative state (GOS 1 and 2), and
group 2 was formed by patients who recovered conscious-
ness (GOS 3, 4 and 5). A patient was considered conscious
if awake or capable of following simple commands at least
once.
Statistical analysis
Continuous data are presented as means and SD, and nonpar-
ametric data as medians and interquartile range. Student's t
test and the Mann–Whitney U test were used to compare con-
tinuous data; Fisher's exact test was used to compare propor-
tions. The discriminative power of NSE to predict an
unfavorable outcome was determined by analysis of receiver-
operating characteristics. The significance level was set at p <
0.05. Statistical analysis was performed with the Statistical
Package for the Social Sciences (SPSS) version 12.0 (SPSS
Inc., Chicago, IL, USA).
Results
Of the 45 patients evaluated, two were excluded from the anal-
ysis because sample hemolysis prevented NSE measurement.
Of the remaining 43 patients, 30 (69.8%) died (GOS 1) and
four (9.3%) developed a persistent vegetative state (GOS 2).
Thus, 34 patients were included in group 1. The outcome after
6 months was favorable (GOS 3, 4 and 5) in nine patients
(20.9%), who were included in group 2. One of them survived
with severe disability (GOS 3); eight survived with minimal dis-
ability (GOS 4 and 5).Page 2 of 6
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The groups were similar in terms of age, sex, duration of resus-
citation efforts, and need for sedation. The GCS score was
significantly lower in group 1 than in group 2. All patients in
group 2 presented pupillary reactivity to light, in contrast with
20 patients (59%) in group 1. This comparison was signifi-
cantly different.
As shown in Figure 1, NSE levels measured between 12 and
36 hours were significantly higher in group 1 (median 44.24
ng/ml, range 8.1 to 370) than in group 2 (median 25.26 ng/ml,
range 9.28 to 55.41; p = 0.034). NSE levels were significantly
higher in group 2 patients (median 25.26 ng/ml, range 9.28 to
55.41) than in controls (median 9.34 ng/ml, range 8.39 to
10.53; p = 0.026).
The prognostic value of serum NSE in predicting unfavorable
outcome was evaluated with a receiver operating characteris-
tics curve. The area under the curve was 0.73 ± 0.08 (95%
confidence interval (CI) 0.56 to 0.90; Figure 2). When a cutoff
value of 60 ng/ml was established, a specificity of 100% (95%
CI 66 to 100%) and a sensitivity of 35% (95% CI 19 to 53%)
were obtained, with positive and negative predictive values of
100% (95% CI 73 to 100%) and 29% (95% CI 14 to 48%),
respectively.
Discussion
The most important finding of our study was the observation
that increased NSE levels between 12 and 36 hours after in-
hospital cardiac arrest are markers of ischemic brain damage
and of unfavorable outcome. NSE levels measured early in the
course of brain injury were significantly higher in patients with
Table 1
Baseline characteristics of 43 patients resuscitated from in-hospital cardiac arrest
Characteristic Group 1 (GOS 1/2) Group 2 (GOS 3–5) p
n 34 9 -
Age, mean ± SD (years) 63.9 ± 14 64.7 ± 11 0.892
Male sex, n (percentage) 14 (41) 6 (66) 0.263
Initial rhythm
VF/VT, n (percentage) 4 (12) 4 (44) 0.046
PEA/asystole, n (percentage) 30 (88) 5 (55)
Low-flow time, median [range], (minutes) 11.5 [5–90] 13 [3–35] 0.952
GCS score, mean ± SD 6.1 ± 3 12.1 ± 3 < 0.001
Pupillary reaction to light, n (percentage) 20 (59) 9 (100) 0.020
Sedation use, n (percentage) 10 (29) 1 (11) 0.407
∆t from NSE sampling, mean ± SD (hours) 20.2 ± 8.3 28.4 ± 8.7 0.013
GOS, Glasgow outcome scale; VF, ventricular fibrillation; VT, ventricular tachycardia; PEA, pulseless electrical activity; GCS, Glasgow Coma 
Scale; ∆t, time elapsed from cardiopulmonary resuscitation until blood sampling for NSE measurement; NSE, neuron-specific enolase.
Table 2
Studies of serum neuron-specific enolase to predict unfavorable outcome after cardiac arrest












[26] No 24 45 20 >17 40 98
[23] Not specified 24 27 35 >20 51 89
[12] No 72 18 25 >33 65 100
[24] No 72 28 24 >16.4 70 100
[25] Yes/Noa 48 34 76 >25 59 100
[13] Yes/Nob 72 28 69 >65 50 96
[27] Yes/Noc 24 51d 356d >33 44 100
This study Yes 12–36 34 9 >60 35 100
CPR = cardiopulmonary resuscitation; NSE = neuron-specific enolase. a77% out-of-hospital arrests; b56% were out-of-hospital arrests; c85% 
were out-of-hospital arrests; dNSE levels were determined in 231 of 407 patients.Page 3 of 6
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favorable outcomes (GOS 3, 4 and 5) after 6 months.
Of the 43 patients analyzed after in-hospital cardiac arrest, 30
(69.8%) died and four (9.6%) remained in a persistent vegeta-
tive state. This mortality rate is in agreement with that
described for other cohorts of in-hospital cardiac arrest.
Peberdy and colleagues [19], for example, reported an 83%
in-hospital mortality rate.
The GCS score was significantly lower in non-survivors and in
patients who evolved to a persistent vegetative state than in
those who survived after 6 months. Edgren and colleagues
[20] have reported that absent motor response to pain and
absent pupillary reactivity to light at 48 hours are good clinical
parameters for the prediction of poor outcomes after global
cerebral ischemia. The main limitation of performing a neuro-
logical examination in those patients is the need for sedation,
which can grossly interfere with the evaluation.
It is known that NSE values are relatively low at the beginning
of ischemic brain injury, with low predictive power in the first 6
hours. Böttiger and colleagues [21] were able to demonstrate
prognostic usefulness only after 24 hours, and Rosén and col-
leagues [22] after 48 hours. In contrast, our study raised evi-
dence that it is possible to establish prognosis at an earlier
time. NSE measurements were made earlier in this study and
samples were collected not at specific times but at any time
between 12 and 36 hours. Although the absence of time
course measurements could be a limitation, the fact that sam-
pling does not need to be made at a defined time point greatly
increases the clinical applicability of using NSE levels as a
marker of prognosis after cardiac arrest, because this step can
be included as part of the routine laboratory workup. In addi-
tion, our results show that we were able to maintain prognostic
accuracy. As reported by Fogel and colleagues [23] and Sch-
oerkhuber and colleagues [24], we observed significantly
higher NSE levels in patients with poor outcome. Those
authors, however, suggest that measurements be made after
72 hours, when NSE levels peak.
The difference in terms of time at NSE sampling between the
groups, despite being a methodological limitation, is unlikely to
have compromised the present results, because NSE has an
ascending curve with peak values at about 72 to 96 hours
[24,25]. Because sampling was performed earlier in group 1,
we would probably have found an even greater difference
between the two groups had the samples been collected at
the same time.
To predict poor outcome in an individual patient, a highly spe-
cific marker is essential. The main reason for this is to avoid an
unnecessarily pessimistic prognosis. For an NSE concentra-
tion of 60 ng/ml, a specificity of 100% and a sensitivity of 35%
were obtained to indicate poor prognosis, with positive and
negative predictive values of 100% and 29%, respectively.
Twelve of the 43 patients studied had NSE levels above the
cutoff point, and all of them died. Had NSE levels been used
to make decisions about withholding or withdrawing critical
care in these patients, there would have been a theoretical
decrease of 63 days in the intensive care unit in this cohort. It
Figure 1
Neuron-specific enolase levels (ng/ml) after in-hospital cardiac arrest. 
Median, interquartile ranges and 5 to 95% centiles are shown. GOS, 
Glasgow outcome scale.
Figure 2
Receiver operating characteristics curve for neuron-specific enolase levels after in-hospital cardiac arrest
levels after in-hospital cardiac arrest. AUC, area under curve; CI, confi-
dence interval.Page 4 of 6
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lished retrospectively, and therefore requires further validation.
Table 2 compares sensitivity and specificity and other relevant
aspects in the present and previous studies [12,13,23-27].
Currently, the most accepted method for establishing progno-
sis in anoxic encephalopathy after cardiac arrest is the meas-
urement of bilateral cortical response to somatosensory
evoked potential (SSEP) [28], which is not widely available in
our and other settings [23,25]. In contrast, determination of
NSE levels can be done at low cost, is easily performed at the
bedside and is not influenced by sedation, as occurs with neu-
rological examination. In this study, 25% of the patients
received sedatives. This makes the determination of NSE lev-
els a very attractive ancillary prognostic method to be used
after cardiopulmonary resuscitation. Zandbergen and col-
leagues [27] have recently shown that unfavorable outcome
could be reliably predicted with both SSEP and NSE as early
as 24 hours after a cardiac arrest in a cohort of 407 normoth-
ermic patients, most of whom were survivors of an out-of-hos-
pital cardiac arrest. Using a predefined cutoff value of 33 ng/
ml, NSE measurements were performed at least once in 231
patients and a 100% specificity was reached for unfavorable
outcome, measured by the GOS a month after the event.
Despite the fact that the results of SSEP and NSE overlapped
only partly, those authors state that both tests were superior to
all clinical tests.
Other biochemical markers have been studied to predict out-
come after anoxic encephalopathy. S100 B is a protein origi-
nating in glial cells, in contrast with NSE, which is of neuronal
origin. S100 B has been shown to be a good predictor of neu-
rological recovery in patients surviving cardiac arrest
[12,13,29], and it seems to have a good correlation with NSE
in those patients [22]. High levels of creatinine kinase-BB
isoenzyme in cerebrospinal fluid have also been associated
with worse neurological outcome after ischemic brain damage
[30].
Recently, therapeutic hypothermia has been shown to improve
neurological outcomes in patients surviving cardiac arrest
caused by ventricular fibrillation [31,32]. A recent study sug-
gests that the use of therapeutic hypothermia reduces the
prognostic value of NSE and S100 B to predict poor out-
comes after cardiac arrest [29], which does not seem to hap-
pen with the use of evoked potentials [33].
The present results are not generalizable to a larger population
of cardiac arrest cases, because we studied only in-hospital
cardiac arrests. Nevertheless, these results are in agreement
with, and complementary to, previous NSE studies with out-of-
hospital cardiac arrest populations. A large prospective multi-
centric study to test a predefined cutoff value for NSE, using
multiple samples and including patients treated with therapeu-
tic hypothermia, surviving in-hospital and out-of-hospital
arrests, should be performed before NSE measurements can
be routinely used for decision-making about the maintenance
of care in comatose patients after cardiac arrest.
Conclusion
Our study demonstrates that NSE levels measured early in the
course of ischemic cerebral injury are significantly higher in
patients with unfavorable outcome than in patients with favo-
rable outcome. Considering that prolonged cardiopulmonary
resuscitation can produce irreversible anoxic brain damage,
prognosis should be established as soon as possible. A multi-
modal approach combining several methods for prognostic
evaluation, including neurological examination, electrophysio-
logical studies and NSE measurements, should be used. We
believe that this strategy may provide a more precise progno-
sis for these patients.
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